top of page

Oral Presentations

Titles of Presentations

The following abstracts have been selected for presentation at the meeting:

1. Can delaying onset of diabetes be cost-effective? A simulation study based on NAVIGATOR data

2. Prediction models for the risk of retinopathy in persons with type 2 diabetes. A systematic review

3. Follow up on the 6th Mount Hood Conference: filling the gap to model type 1 diabetes.

4. Data structures and algorithms for modelling conditionally random events in a probabilistic discrete-time simulation model for type 2 diabetes: exploitation of modern C++ features


5. Impact of adjusting diabetes treatment pathways according to disease severity – the case of HbA1c and macular oedema


6. The Importance of Considering Differences in Network Meta-analyses (NMAs): An Example of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) in the Treatment of Type 2 Diabetes Mellitus (T2DM)


7. Costs of hypoglycemia in insulin-treated diabetes in Switzerland: a health economic analysis


8. The estimation of post-treatment HbA1c using a beta regression in the Sheffield Type 1 Diabetes Policy Model


9. Combining parameter and sampling uncertainties within diabetes clinical outcome simulation models


10. Using big data to estimate treatment effects: The impact of statins on HbA1c levels in individuals tested in a community setting


11. Life-expectancy and costs for people with type 2 diabetes


12. Challenges and opportunities for decision modelling from the onset of prediabetes onwards


13. Self-care practice and its associated factors among diabetic patients in addisababa public hospitals, cross sectional study


14. The Importance of HbA1c Evolution in Modeling Type 2 Diabetes Mellitus


15. Cost-effectiveness of Individualizing Glycemic Goals for U.S. Adults with Type 2 Diabetes


16. Cost analysis of insulin treatment regimens for patients with type 1 diabetes in the Ukrainian setting


17. The Importance of Capturing Cardiovascular Benefits Not Mediated by Traditional Risk Factors in Type 2 Diabetes Mellitus (T2DM) Modeling: An Example Using Statins and the UKPDS 82 Risk Engine


18. Replacing input probability distributions with mean values can bias simulation output: an illustration using the CORE diabetes model.


19. Impact of Improving Diabetes Care on Quality Adjusted Life Expectancy (QALE) and Costs: A 30-Year Perspective


20. Implications of introducing patient heterogeneity in cost effectiveness modeling


21. Estimating the cost effectiveness of a patient-directed mealtime insulin titration algorithm


22. How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes? A systematic review

23. Breaking away from central tendencies: Using more flexible and informative economic models of the cost of healthcare for people with type 2 diabetes

24. A Covaried, Target-Based, Patient-Level Model of HbA1c Progression in Type 1 Diabetes

bottom of page